What does Zuken do?
Zuken sells engineering software used before physical products are built. CR-8000 helps engineers design printed circuit boards, E3.series helps design wire harnesses, and DS/PDM tools manage engineering data and product design records. License sales create the installed base, while Client Services contracts renew around that base and reached 42.9% of FY3/26 revenue. The investor debate is whether this core business can fund two next growth legs — model-based systems engineering through GENESYS, and 3DIC packaging work — while improving returns on a ¥36.1bn net-cash balance. Key checks are MBSE revenue trajectory, Americas segment losses, and capital-return follow-through.
What has driven the stock over the past two years?
The stock climbed from the ¥3,115 trough on August 5, 2024 to ¥5,820 on July 17, 2025, then gave back part of that move. The rally reflected three things: proof of operating leverage, a clearer capital-return floor, and a three-year mid-term plan. The next four quarters will test whether Client Services growth, MBSE progress, Americas profitability, and capital returns can support the multiple.
01 · THE RALLY Zuken's software sits early in the engineering workflow, before hardware is manufactured. CR-8000 is used for electronic design automation (EDA) of printed circuit boards, E3.series is used for wire-harness CAD, and DS/PDM tools manage engineering data across design teams. Once libraries and workflows are embedded, switching costs are high. That makes the revenue model cumulative: license sales build the installed base, Client Services contracts renew around it, and data-management usage deepens with each product generation. In FY3/26, Client Services reached 42.9% of revenue, rising +9.1% versus +3.5% for licenses, while fiscal year-end backlog rose to ¥26.22bn (+25%). The share rally from ¥3,115 on August 5, 2024 to ¥5,820 on July 17, 2025 followed three disclosures: a November 2024 DOE-≥5% capital-return floor, FY3/25 operating profit +12.4% on revenue +5.9% showing operating leverage, and a new ¥3bn buyback plus the FY3/28 mid-term plan at ¥49bn revenue and ¥7.4bn operating profit.
02 · THE REVERSAL On August 6, 2025 the Q1 FY3/26 tanshin disclosed sales ¥9,119M (+1.1%) and operating profit ¥827M (−3.4%) — an optical reversal that read as the front edge of a back-end-loaded year. The reasoning was visible in the same disclosure: the MTP had explicitly placed the heavier sales lift in years two and three, and the Q1 personnel cost increase reflected the ¥200M-per-year 3DIC research budget that management had built into the plan as a structural investment phase. From the July 17 peak of ¥5,820 the share compressed to ¥4,500 by late January 2026, a 23% retracement against a backdrop in which the company's actual operating disclosures kept ratifying the back-half acceleration: October 2025 saw Artisan Partners file an 8.11% large-holder report and become a significant foreign holder; November 2025 added a ¥100 commemorative dividend for the company's fiftieth anniversary, lifting FY3/26 total DPS to ¥200; December 2025's MTP-progress briefing reframed the strategic frame around three keywords — semiconductor, autonomous AI, and model-based systems engineering — and announced participation in the Resonac-led JOINT3 consortium for next-generation organic-panel substrate packaging. The market read the timing-of-cost mismatch as an MTP-execution question and held the price down even as the order backlog kept widening.
03 · WHERE WE STAND NOW The FY3/26 tanshin filed on May 14, 2026 closed the question on the back-half. Sales landed at ¥43,101M (+5.8%); operating profit reached ¥5,865M (+8.8%), beating the ¥5,600M guide by 4.7%; ordinary profit climbed to ¥7,134M (+20.2%) on a record ¥900M equity-method profit contribution from the Business Engineering Corp affiliate; group operating margin expanded forty basis points to 13.6%; and the FY3/27 guide called for the operating-profit growth rate to accelerate from +8.8% to +14.2% on revenue growth of +6.7%, with ordinary dividend per share raised to ¥150 — a 50% lift on the FY3/25 ordinary base of ¥100. The ¥3bn yen-cap buyback authorized in May 2025 completed in late January 2026 — the second consecutive year of near-full-envelope execution after FY3/25's ¥2.5bn programme — bringing the trailing-twelve-month total payout to 134% of net income and the treasury share count to 5.3% of the issued base. What the next four quarters resolve is whether the FY3/27 ¥6.7bn guide proves conservative against the MTP-end ¥7.4bn target, whether the eight-year Americas-segment operating loss closes during the plan as the GENESYS MBSE leg scales toward FY3/28's ¥3bn target, and whether the FY3/27 results introduce a deployment framework for the ¥36.1bn cash pile that the two-year buyback program has only just begun to absorb.
Live Investor Debates
Three open questions surface in the company's recent quarterly disclosures and in the FY3/26 results briefing Q&A. Each one settles a different part of the multiple.
What could change over the next twelve months?
Three disclosure or capital-policy levers based on gaps already visible in company materials. Each could change how investors price the stock without requiring higher near-term earnings.
What has to be true for the stock to work from here?
Three internally consistent JII analytical scenarios for the next four quarters. These are not company guidance and not predictions; each case uses a different combination of disclosed operating and capital-allocation outcomes.
- Q3 FY3/27 (Feb 2027) prints group operating margin below 13% with revenue growth below +5% year-on-year.
- FY3/27 Americas segment operating loss exceeds ¥-400M; MTP mid-point MBSE revenue below ¥2.0bn.
- FY3/27 results retain DOE 5% as the floor; no incremental buyback authorization; cash crosses ¥38bn.
- B-EN-G equity-method profit normalizes from ¥900M back toward ¥500M; ordinary income growth turns negative.
- FY3/28 MTP guidance held but with explicit caveats on the back-end-loaded ¥7.4bn operating-profit target.
The bear band of ¥3,600–¥4,200 implies ~7–9x FY3/27 forward EV/EBIT — in line with the only listed JP software peer, Business Engineering (4828) at ~7.2x, and at parity with the JP private-buyer 7–10x cohort that Renesas paid for Altium in February 2024.
- FY3/27 prints sales ¥46.0bn ±2%, OP ¥6.7bn ±5%, NP ¥5.7bn ±5%.
- FY3/27 ordinary dividend ¥150 paid; one additional ~¥3bn buyback authorized at the FY3/27 results.
- Americas segment narrows the operating loss further to ¥-200M or breakeven; MBSE revenue tracks ¥2.5bn.
- Asia segment holds the 29% operating margin on ¥2.4bn of revenue; Europe stabilizes at 10% margin.
- At least one of (MBSE customer count, MTP-component revenue table, stepped DOE floor at 7%) materializes during FY3/27.
- FY3/27 operating profit exceeds the ¥6.7bn guide by 5% or more; group operating margin lands at or above 15%.
- Board authorizes a DOE 7% floor or an explicit recurring buyback above ¥3bn per year at the FY3/27 results.
- 3DIC program produces a disclosed customer win (Resonac JOINT3 conversion or IBM AI-chip packaging commercial license).
- Americas segment reaches operating breakeven during FY3/27; MBSE revenue at MTP mid-point lands at or above ¥2.7bn.
- FY3/28 MTP target ¥7.4bn looks achievable on FY3/27 trajectory — the back-end-loaded final step is set up by H1 FY3/28 visibility.
The bull band of ¥5,400–¥6,400 implies ~11–14x FY3/27 forward EV/EBIT — a re-rate above the ~7.2x its lone listed JP peer (4828) trades on, yet still well below the global EDA peer band of 17–22x at Cadence and Synopsys. The implied multiple at the upper bull band sits two turns above today's 9.8x.
This is not investment advice.
Japan Investor Interface Co., Ltd. ("JII") is an investor-relations (IR) consultancy. JII is not a registered investment advisor, financial advisor, broker-dealer, or securities firm in any jurisdiction. JII is not registered as a Financial Instruments Business Operator under Japan's Financial Instruments and Exchange Act. JII does not have an Investment Advisory and Agency Business registration and does not provide investment advice or solicit the purchase, sale, or holding of any security.
JII Compounders is an editorial publication. Each profile is an analytical study of how publicly disclosed information about a Japanese listed company has been received by the market. It is intended for educational and research purposes for IR professionals, finance students, journalists, and other readers interested in corporate disclosure practice. Nothing in this publication constitutes a recommendation, opinion, suggestion, or solicitation to buy, sell, or hold any security, derivative, or other financial instrument. Price targets, scenario ranges, multiples, and comparable-company references are illustrative of analytical method only and must not be interpreted as JII's investment opinion. JII does not have an investment opinion on any security discussed.
No reliance. The information presented may be incomplete, out of date, or incorrect. Forward-looking statements are inherently uncertain. Past price performance does not indicate future results. Estimates and scenario figures are not predictions and may not be achieved. JII makes no representation or warranty, express or implied, regarding the accuracy, completeness, timeliness, or reliability of any information in this publication.
No fiduciary or advisory relationship. Reading this publication does not create any advisory, fiduciary, or professional relationship between you and JII. Before making any investment, tax, accounting, legal, or other decision, you should consult qualified, licensed advisors in your jurisdiction and conduct your own independent due diligence based on primary disclosures issued by the company concerned.
Conflicts & positions. JII may provide paid IR diagnostic, translation, or interpretation services to Japanese listed companies, including companies discussed in this publication. JII does not trade in or hold positions in the securities of companies profiled. Where a JII engagement exists with a profiled company, that fact will be disclosed at the top of the profile.
Trademarks & data. Company names, logos, tickers, and product names referenced are the property of their respective owners. Share-price data is licensed from third-party providers. TradingView is a trademark of TradingView, Inc. All rights reserved.
本資料は、日本の金融商品取引法に基づく投資助言・代理業ではなく、特定の有価証券の売買その他の取引の勧誘・推奨を目的とするものではありません。本資料は教育・研究を目的とした分析記事であり、JII（株式会社ジャパン・インベスター・インターフェース）は、本資料の内容に基づく投資判断について一切の責任を負いません。投資の判断はご自身の責任と独立した調査に基づいて行ってください。